Misoprostol for induction of labour to terminate pregnancy in the second or third trimester for women with a fetal anomaly or after intrauterine fetal death

Dodd, Jodie M; Crowther, Caroline A

doi:10.1002/14651858.cd004901.pub2

Cited by 38 publications

(41 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The side effects and complications of using vaginal misoprostol in the present study and in other studies like Chittacharoen et al, 16 Nyende et al, 3 De Hues et al, 15 Ezechi et al, l4 Dodd et al 13 and Easmin et al 8 included nausea, diarrhoea, vomiting, pyrexia, retained placenta, postpartum haemorrhage and hyperstimulation syndrome. Diarrhoea and elevated temperature were found to increase with increasing dose of misoprostol in the present study and the study by Dodd et al 13 …”

Section: Discussionsupporting

confidence: 64%

See 1 more Smart Citation

Induction of Labour With Vaginal Misoprostol in Intrauterine Foetal Death

Sarma¹

2017

jemds

View full text Add to dashboard Cite

BACKGROUNDIntrauterine foetal death is an unfortunate event met in obstetric practice. Misoprostol has emerged as an efficient and relatively safe drug to deliver the baby in this condition. The objective of this study is to evaluate the safety and efficacy of vaginal misoprostol tablets for the induction of labour in intrauterine foetal death. MATERIALS AND METHODSThis uncontrolled clinical trial was performed on 100 women with intrauterine foetal death from January 2016 to December 2016 at Silchar Medical College and Hospital. All women were properly evaluated. Informed consent was taken and vaginal misoprostol tablets at a dose of 50 mcg 4 hourly was used to induce labour. The results were assessed. RESULTSIn a study of 100 women, mean natural age was 26.21 ± 4.98 years, mean gestational age was 38.81 ± 4.26 weeks, 61% women were primigravida and the rest were multigravida; 80% were booked cases, 72% belonged to rural areas and 76% were illiterates. The mean initial Bishop's score was 2.23 ± 1.82 (range 0 to 6), while following induction with misoprostol the mean Bishop's score was 6.98 ± 2.1, the mean difference was 4.75. P value was statistically significant. The mean induction-labour onset interval was 10 ± 6.65 hours and the mean induction-delivery interval was 13.60 hours with 46.46% women delivering within 12 hours. The mean misoprostol dose required was 152.5 ± 88.5 mcg. Induction was successful in all women, but laparotomy was needed in 1 women because of uterine rupture. The side effects noted were nausea (7%), vomiting (2%), diarrhoea (4%), fever (5%), uterine hyperstimulation (4%), ruptured uterus (1%), retained placenta (3%) and atonic post-partum haemorrhage (3%). CONCLUSIONMisoprostol is an effective, economic and safe drug that can be used for cervical ripening and labour induction in intrauterine foetal death. Clinical significance-the response to misoprostol is influenced by the gestational age, Bishop's score and parity of the women.

show abstract

Section: Discussionsupporting

confidence: 64%

“…P value being 0.001, which was significant. A 98% success rate of induction was shown by Easmin S et al, 8 whereas Dodd et al 13 have noted comparable rates of vaginal delivery within 24 hours with a similar induction to birth interval in their assessment comparing vaginal misoprostol with other prostaglandin preparations.…”

Section: Discussionmentioning

confidence: 91%

Induction of Labour With Vaginal Misoprostol in Intrauterine Foetal Death

Sarma¹

2017

jemds

View full text Add to dashboard Cite

show abstract

“…So it 8 was administered empirically awai ng reports. Vaginal misoprostol was successfully used for expulsion of fetus a er 9 …”

Section: Discussionmentioning

confidence: 99%

Severe ARDS due to Influenza A (H1N1) pdm09 Infection During Pregnancy Followed by Intrauterine Fetal Death at Alka Hospital, Lalitpur

Shrestha

Bhuju²,

Manandhar

et al. 2017

Birat J. Health Sci.

View full text Add to dashboard Cite

Pandemic due to Influenza A (H1N1) pdm 09 has been a significant cause of morbidity and mortality worldwide. Pregnant women are at risk of severe disease and ARDS, with rapid progression of disease. There is increased risk of fetal loss. Little evidence exists regarding the management of ARDS in pregnancy. Here we report a case of H1N1 virus infection in a pregnant woman in third trimester complicated by severe ARDS and intra-uterine fetal death. Fetus was successfully expelled using vaginal Misoprostol, which was followed by improvement in oxygenation indices. However, the patient died of refractory hypotension. Influenza vaccination in the high risk population may be invaluable. Birat Journal of Health Sciences Vol.2/No.1/Issue 2/ Jan - April 2017, Page: 227-229

show abstract

“…22,30,33,36,48 Dose and dosing interval should be selected so as to generate sufficient and sustained uterine activity while minimising adverse effects 35 • The sensitivity of the uterus to prostaglandins increases with gestational age therefore decreasing amounts of Misoprostol may be required with increasing gestational age. 35,46 Adjust dose based on clinical experience and judgement • Refer to Table 10 and Table 11 • In comparison to other prostaglandin preparations (Gemeprost, Prostaglandin E 2 and Prostaglandin F 2 alpha), Misoprostol, is more cost effective, more stable at room temperature and has fewer side effects 36,41,48 Adverse effects…”

Section: Dosagementioning

confidence: 99%